Drugs / BOS172767 enantiomer E1 or E2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04514237 | Sep 2019 → Jan 2020 | — | Boston Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BOS172767 enantiomer E1 or E2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04514237 ↗ |
| Route | Oral | “Oral tablets” NCT04514237 ↗ |